About ECM Therapeutics
ECM Therapeutics is a company based in Warrendale (United States) founded in 2018. ECM Therapeutics has raised $26.1 million across 1 funding round. ECM Therapeutics offers products and services including ECM Therapeutic Products and Extracellular Vesicles. ECM Therapeutics operates in a competitive market with competitors including SpringWorks Therapeutics, Augmenix, AmacaThera, Regentis Biomaterials and LifeSprout, among others.
- Headquarter Warrendale, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ecm Therapeutics Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$26.1 M (USD)
in 1 rounds
-
Latest Funding Round
$26.1 M (USD), Series B
May 28, 2018
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ECM Therapeutics
ECM Therapeutics offers a comprehensive portfolio of products and services, including ECM Therapeutic Products and Extracellular Vesicles.
Products from extracellular matrix for tissue repair and inflammation reduction.
Signaling molecules in ECM for regenerative applications in medical treatments.
People of ECM Therapeutics
Unlock access to complete
Funding Insights of ECM Therapeutics
ECM Therapeutics has successfully raised a total of $26.1M through 1 strategic funding round. The most recent funding activity was a Series B round of $26.1 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by ECM Therapeutics
Investment portfolio details for ECM Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ECM Therapeutics
Detailed financials for ECM Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ecm Therapeutics Comparisons
Peer comparison for ECM Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ECM Therapeutics
ECM Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SpringWorks Therapeutics, Augmenix, AmacaThera, Regentis Biomaterials and LifeSprout, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for cancer and rare diseases.
|
|
| Locked | Locked | Locked |
Hydrogel spacers are provided for prostate cancer radiation therapy.
|
|
| Locked | Locked | Locked |
Injectable hydrogel platform developed for therapeutic medical applications.
|
|
| Locked | Locked | Locked |
Regentis Biomaterials is focused on tissue repair hydrogel technology.
|
|
| Locked | Locked | Locked |
Synthetic soft tissue substitutes for cosmetics and reconstructive surgery
|
|
| Locked | Locked | Locked |
Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation
|
Detailed competitors of ECM Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ecm Therapeutics
Complete news archive for ECM Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ECM Therapeutics
ECM Therapeutics was founded in 2018.
ECM Therapeutics is headquartered in Warrendale, United States. It is registered at Warrendale, Pennsylvania, United States.
ECM Therapeutics is a funded company, having raised a total of $26.1M across 1 funding round to date.
ECM Therapeutics was founded in 2018 and is based in Warrendale, United States. Focus is placed on the development of diagnostic and therapeutic products sourced from extracellular matrix, a naturally occurring material. These products address diseases and injuries, including an ECM hydrogel named EsophaGel designed to halt and reverse esophageal cancer progression and precursor stages linked to gastric reflux. Operations center on biotechnology applications for medical treatments.
ECM Therapeutics's top competitors include SpringWorks Therapeutics, AmacaThera and Augmenix.
ECM Therapeutics offers ECM Therapeutic Products and Extracellular Vesicles.